These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 505533)

  • 21. Development of large-scale fractionation methods. VI. An improved method for preparation of antihemophilic factor.
    Wickerhauser M; Mercer JE; Eckenrode JW
    Vox Sang; 1978; 35(1-2):18-31. PubMed ID: 664566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation of stable intermediate-purity factor VIII concentrate with a note on high-purity factor VIII.
    Margolis J; Rhoades P
    Vox Sang; 1979; 36(6):369-74. PubMed ID: 494575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of factor VIII recovery in cryoprecipitate.
    Kasper CK; Myhre BA; McDonald JD; Nakasako Y; Feinstein DI
    Transfusion; 1975; 15(4):312-22. PubMed ID: 1166504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.
    Burnouf T; Burnouf-Radosevich M; Huart JJ; Goudemand M
    Vox Sang; 1991; 60(1):8-15. PubMed ID: 1905084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Production of high-potency cryoprecipitate from exercised blood donors and the treatment of hemophilia A with this material.
    Strand CL; Beene JR; Geiger T; Eckel MO; Kunkel K; Bull G
    Am J Clin Pathol; 1974 Oct; 62(4):496-501. PubMed ID: 4415312
    [No Abstract]   [Full Text] [Related]  

  • 26. Cryoprecipitate of intermediate purity produced in a closed thaw-siphon system from DDAVP stimulated blood donor plasma.
    Konecka G; Bykowska K; Ludwicka A; Letowska M; Wegrzynowicz Z; Sablinski J; Lopaciuk S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):565-70. PubMed ID: 1714861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cryoprecipitation and dextran precipitation in obtaining factor VIII concentrates: comparative protein chemical studies].
    Liebe S; Kubel M; Wegner H
    Z Gesamte Inn Med; 1974 Mar; 29(6):232-6. PubMed ID: 4409089
    [No Abstract]   [Full Text] [Related]  

  • 28. Preparation of antihemophilic factor and fibronectin from human plasma cryoprecipitate.
    Horowitz B; Lippin A; Chang MY; Shulman RW; Vandersande J; Stryker MH; Woods KR
    Transfusion; 1984; 24(4):357-62. PubMed ID: 6431661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clearance of cryoprecipitated factor VIII in canine hemophilia A.
    Aufderheide WM; Skinner SF; Kaneko JJ
    Am J Vet Res; 1975 Apr; 36(4 Pt.1):367-70. PubMed ID: 1124873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of the primary anticoagulant on the recovery of factor VIII in cryoprecipitate.
    de Wit HJ; Scheer G; Muradin J; van der Does JA
    Vox Sang; 1986; 51(3):172-5. PubMed ID: 3101286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation of and clinical experience with antihemophilic factor concentrates.
    Johnson AJ; Karpatkin MH; Newman J
    Thromb Diath Haemorrh Suppl; 1968; 35():49-59. PubMed ID: 5317364
    [No Abstract]   [Full Text] [Related]  

  • 32. Influence of heparin and calcium chloride on assay, stability, and recovery of factor VIII.
    Morgenthaler JJ; Zuber T; Friedli H
    Vox Sang; 1985; 48(1):8-17. PubMed ID: 3918394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate.
    Allersma DP; Smid WM; van der Does JA; van der Meer J; Briët E
    Thromb Haemost; 1996 Feb; 75(2):261-6. PubMed ID: 8815573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilization of the residual plasma following preparation of factor VIII cryoprecipitate.
    Oberman HA; Penner JA
    JAMA; 1968 Sep; 205(12):819-21. PubMed ID: 5695503
    [No Abstract]   [Full Text] [Related]  

  • 35. [Factor VIII concentrate, highly purified and heated in solution (author's transl)].
    Heimburger N; Schwinn H; Gratz P; Lüben G; Kumpe G; Herchenhan B
    Arzneimittelforschung; 1981; 31(4):619-22. PubMed ID: 6788045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cryoprecipitation and dextran precipitation in obtaining factor VIII concentrates: results of redetecting antihemophilic globulin A in a patient].
    Kubel M; Wegner H; Liebe S
    Z Gesamte Inn Med; 1974 Mar; 29(6):236-40. PubMed ID: 4409090
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of factor VIII-rich cryoprecipitate and the plasma fibronectin-rich, heparin-precipitable fraction prepared from single-donor plasma units.
    Menitove JE; Amrani DL; Meh D; Frenzke M; Mosesson MW
    Transfusion; 1987; 27(6):491-5. PubMed ID: 3500532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A heat-treated factor VIII concentrate prepared by controlled-pore glass adsorption chromatography.
    Benny AG; Scott RH; Woodfield DG
    Transfusion; 1987; 27(2):174-7. PubMed ID: 3103269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
    Benny AG; Ockelford PA; Johns AS; Scott RH; Woodfield DG; Berry EW
    J Clin Pathol; 1988 Sep; 41(9):945-7. PubMed ID: 3142936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate.
    Prowse CV; Griffin B; Pepper DS; Dickson AJ; McQuillan TA; Dickson IH; Foster PR
    Thromb Haemost; 1981 Oct; 46(3):597-601. PubMed ID: 6797090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.